- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
504
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
504 companies
Merus
Market Cap: US$3.0b
A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
MRUS
US$43.06
7D
2.6%
1Y
8.2%
Sotera Health
Market Cap: US$3.0b
Provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
SHC
US$10.48
7D
-1.1%
1Y
-3.9%
Scholar Rock Holding
Market Cap: US$2.8b
A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
SRRK
US$30.75
7D
16.9%
1Y
120.4%
Protagonist Therapeutics
Market Cap: US$2.8b
A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
PTGX
US$46.28
7D
13.2%
1Y
83.5%
Crinetics Pharmaceuticals
Market Cap: US$2.8b
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CRNX
US$30.42
7D
13.3%
1Y
-29.3%
Catalyst Pharmaceuticals
Market Cap: US$2.7b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$22.52
7D
5.0%
1Y
46.8%
Xenon Pharmaceuticals
Market Cap: US$2.7b
A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.
XENE
US$35.11
7D
11.8%
1Y
-12.0%
Viking Therapeutics
Market Cap: US$2.6b
A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
VKTX
US$23.94
7D
11.2%
1Y
-63.0%
Immunovant
Market Cap: US$2.5b
A clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
IMVT
US$15.15
7D
2.4%
1Y
-46.5%
Veracyte
Market Cap: US$2.5b
Operates as a diagnostics company in the United States and internationally.
VCYT
US$31.14
7D
2.9%
1Y
62.2%
ACADIA Pharmaceuticals
Market Cap: US$2.4b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$14.73
7D
4.4%
1Y
-13.7%
MoonLake Immunotherapeutics
Market Cap: US$2.3b
A clinical stage biopharmaceutical company, engages in developing therapies.
MLTX
US$38.33
7D
12.8%
1Y
-9.3%
Twist Bioscience
Market Cap: US$2.3b
Manufactures and sells synthetic DNA-based products.
TWST
US$36.80
7D
0.5%
1Y
29.8%
Apellis Pharmaceuticals
Market Cap: US$2.3b
A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
APLS
US$18.20
7D
-3.1%
1Y
-61.7%
Amneal Pharmaceuticals
Market Cap: US$2.3b
A global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
AMRX
US$7.36
7D
5.6%
1Y
37.3%
ImmunityBio
Market Cap: US$2.1b
A commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
IBRX
US$2.47
7D
0.4%
1Y
-49.7%
Amicus Therapeutics
Market Cap: US$2.1b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$6.83
7D
4.9%
1Y
-33.9%
Vericel
Market Cap: US$2.0b
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
VCEL
US$41.23
7D
-1.6%
1Y
-6.0%
Ligand Pharmaceuticals
Market Cap: US$2.0b
A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
LGND
US$104.97
7D
3.6%
1Y
44.7%
Biohaven
Market Cap: US$1.9b
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide.
BHVN
US$20.37
7D
18.9%
1Y
-51.7%
Mirum Pharmaceuticals
Market Cap: US$1.9b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$39.10
7D
-0.05%
1Y
65.9%
Apogee Therapeutics
Market Cap: US$1.9b
A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.
APGE
US$33.11
7D
10.6%
1Y
-31.5%
Denali Therapeutics
Market Cap: US$1.8b
Denali Therapeutics Inc., discovers, develops, and delivers barrier-crossing therapeutics for neurodegenerative, lysosomal, and other serious diseases in the United States.
DNLI
US$12.74
7D
1.9%
1Y
-23.3%
NewAmsterdam Pharma
Market Cap: US$1.8b
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
NAMS
US$16.34
7D
9.7%
1Y
-15.9%
Supernus Pharmaceuticals
Market Cap: US$1.7b
A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.
SUPN
US$30.76
7D
-1.0%
1Y
6.5%
Bausch Health Companies
Market Cap: US$1.7b
Operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally.
BHC
US$5.10
7D
16.7%
1Y
-40.7%
Endo
Market Cap: US$1.6b
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.
NDOI
US$21.33
7D
-1.9%
1Y
n/a
Harmony Biosciences Holdings
Market Cap: US$1.6b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$28.46
7D
-1.8%
1Y
-2.0%
Centessa Pharmaceuticals
Market Cap: US$1.6b
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.
CNTA
US$12.30
7D
9.1%
1Y
16.8%
Agios Pharmaceuticals
Market Cap: US$1.6b
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
AGIO
US$27.66
7D
9.3%
1Y
-6.0%
CG Oncology
Market Cap: US$1.5b
A late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer.
CGON
US$20.64
7D
17.1%
1Y
-41.6%
Arcutis Biotherapeutics
Market Cap: US$1.5b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$13.01
7D
-3.2%
1Y
37.7%
Kiniksa Pharmaceuticals International
Market Cap: US$1.5b
A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
KNSA
US$20.21
7D
8.4%
1Y
19.7%
ARS Pharmaceuticals
Market Cap: US$1.5b
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$14.88
7D
12.4%
1Y
76.3%
Disc Medicine
Market Cap: US$1.4b
A clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
IRON
US$42.17
7D
19.7%
1Y
40.5%
ANI Pharmaceuticals
Market Cap: US$1.4b
A biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
ANIP
US$69.21
7D
6.3%
1Y
7.2%